D ual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor antagonist is currently recommended for at least 1 year after percutaneous coronary intervention (PCI) with drug-eluting stents (DES) to reduce the incidence of stent thrombosis and major adverse cardiac events (MACE). 1 Clopidogrel is the most widely used P2Y12 receptor Background-Certain proton pump inhibitors (PPIs) interfere with clopidogrel metabolism, potentially attenuating P2Y12 receptor inhibition. Previous observational and randomized trials report conflicting results regarding the clinical significance of this pharmacological interaction. We examined the interaction between concomitant administration of PPI and clopidogrel on platelet reactivity and clinical outcomes in the large-scale, prospective Assessment of Dual AntiPlatelet Therapy With Drug-Eluting Stents study. Methods and Results-On-treatment P2Y12 platelet reactivity testing was performed using the VerifyNow assay after clopidogrel loading and successful drug-eluting stent implantation at 11 sites in the United States and Germany. PPIs were prescribed at the discretion of treating physicians; patients were followed for 2 years. High platelet reactivity was defined as P2Y12 reactivity units >208. Of 8582 enrolled patients, 2697 (31.4%) were taking a PPI at the time of coronary intervention. After adjustment for differences in baseline characteristics, PPI use was independently associated with high platelet reactivity (odds ratio, 1.38: 95% confidence interval, 1.25-1.52, P=0.0001). A total of 2162 (25.2%) patients were prescribed a PPI at hospital discharge. In a propensity-adjusted multivariable analysis, discharge PPI use was independently associated with increased risk for postdischarge major adverse cardiac events (cardiac death, myocardial infarction, or ischemia-driven target lesion revascularization) at 2-year follow-up (hazard ratio, 1.21; 95% confidence interval, 1.04-1.42, P=0.02). Conclusions-In patients treated with clopidogrel after successful drug-eluting stents implantation, the concomitant administration of PPI was associated with high platelet reactivity and a greater rate of adverse outcomes during long-term follow-up. Additional studies are warranted to determine the risk-benefit ratio of PPIs in patients with drug-eluting stents treated with clopidogrel. Clinical Trial Registration-URL: http://www.clinicaltrials.gov. Unique identifier: NCT00433966.
Proton Pump Inhibitor Interactions With Clopidogrel
antagonist. Despite the antiischemic benefits of DAPT, their use significantly increases the risk of gastrointestinal bleeding and other hemorrhagic complications, which have been independently associated with increased mortality. [2] [3] [4] Proton pump inhibitors (PPIs) are often used in patients undergoing PCI, either for preexisting conditions, such as gastroesophageal reflux, or to reduce the frequency of gastritis or gastrointestinal bleeding. However, certain PPIs may also interfere with clopidogrel metabolism, potentially attenuating P2Y12 receptor-based platelet inhibition. [5] [6] [7] [8] Whether these potential pharmacodynamic interactions are of clinical relevance is unknown, with prior observational and randomized trials differing with respect to the significance of this pharmacological interaction. [9] [10] [11] [12] [13] [14] [15] [16] [17] The large-scale, prospective, observational, multicenter Assessment of Dual AntiPlatelet Therapy with Drug-Eluting Stents (ADAPT-DES) study 18 used routine platelet reactivity testing for patients undergoing DES implantation and collected data regarding PPI use at the time of PCI and at hospital discharge. We therefore sought to examine the relationship between PPI use, platelet reactivity, and long-term clinical outcomes in ADAPT-DES.
Methods
ADAPT-DES was a large-scale, prospective, international, multicenter registry assessing platelet reactivity in unselected patients with coronary artery disease who were treated with aspirin and clopidogrel and underwent successful placement of one or more DES. The study design and complete inclusion and exclusion criteria have been previously described. 18 Patients with a major complication either during the procedure or before platelet function testing planned bypass surgery after stenting, significant anemia preventing an accurate measurement of platelet reactivity, or those unable to take DAPT were excluded. Otherwise, there were no specific clinical or anatomic exclusion criteria, and a true consecutive all-comers population was recruited. The study was approved by the institutional review board of each participating center, and all patients enrolled provided written informed consent.
After successful PCI, postprocedure platelet reactivity was measured using the VerifyNow Aspirin, P2Y12, and IIb/IIIa assays (Accumetrics, San Diego, CA). Platelet reactivity testing was performed at least 6 hours after a 600 mg loading dose of clopidogrel, 12 hours after a 300 mg loading dose, or after 5 consecutive days of antiplatelet therapy with clopidogrel 75 mg. Platelet reactivity on clopidogrel was assessed as VerifyNow P2Y12 reaction units (PRU), which strongly correlates with the active metabolite of clopidogrel. 19 The treating physicians were blinded to the results of platelet reactivity testing and did not use them for clinical management. All patients received antiplatelet therapy with aspirin indefinitely and clopidogrel for at least 1 year post-PCI.
PPI therapy was administered at the discretion of the treating physician and was recorded as a drug class in the case report form both at the time of PCI and at hospital discharge. Specific PPIs were not reported. Clinical follow-up was scheduled at 30 days, 1 year, and 2 years for all patients. The primary study end point was definite or probable stent thrombosis as defined by the Academic Research Consortium. 20 Other study end points included all-cause mortality, myocardial infarction (MI) defined by Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) criteria, 21 and clinically relevant bleeding defined as the occurrence of either: Thrombolysis in Myocardial Infarction (TIMI) major or minor bleeding, a Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) bleed, an ACUITY major bleed, or any post-discharge bleeding requiring medical attention. 18 MACE was defined as the occurrence of cardiac death, MI, or ischemia-driven target lesion revascularization. All deaths, MIs, and stent thrombosis events were adjudicated by an independent clinical events committee blinded to VerifyNow testing, PPI use, and clinical outcomes.
Statistical Analyses
The present analysis represents a prespecified substudy from the ADAPT-DES protocol. Chi-square or Fisher exact test, as appropriate, was used to compare categorical outcomes. Continuous variables are presented as mean±standard deviation and were compared by Student t test. Multivariable linear regression models were generated to estimate predictors of platelet reactivity as a continuous end point; logistic regression models with multiple relevant covariates (age, sex, hypertension, diabetes mellitus, heart failure, peripheral arterial disease, prior myocardial infarction, prior PCI, prior CABG, renal insufficiency, and acute coronary syndrome presentation) included in a stepwise fashion (P for entry <0.1) were used to generate odds ratios of variables independently associated with high platelet reactivity (HPR) based on the clinically accepted cut point of PRU>208. To adjust for the treatment indication bias for PPI use at discharge, a propensity score was calculated by a multivariable logistic regression analysis. Each clinical outcome was modeled by Cox proportional hazard regression with including relevant baseline variables and the propensity score as a quintile variable. The variables included in these models are age, sex, diabetes mellitus, hypertension, hyperlipidemia, tobacco use, prior MI, renal insufficiency, creatinine clearance, STEMI or NSTEMI, one treated vessel, hemoglobin, WBC, platelet count, VerifyNow P2Y12 >208, and propensity score as a quintile variable. Two-tailed P values <0.05 were considered statistically significant. All analyses were performed using SAS software, version 9.1.3 (SAS Institute, Cary, NC).
Results

Patients and PPI Use
A total of 8665 patients were prospectively enrolled after successful DES placement between January 7, 2008, and September 16, 2010, at 11 medical centers in the United States and Germany. After excluding 82 patients (0.9%) in whom platelet function testing was performed before the protocol-required glycoprotein IIb/IIIa inhibitor washout period and 1 patient who was inadvertently enrolled twice, the final study cohort consisted of 8582 patients. A PPI was administered to 2697 (31.4%) patients at the time of PCI. High-risk baseline patient characteristics were associated with PPI use (Table 1) . Patients
WHAT IS KNOWN
• Certain proton pump inhibitors may interfere with clopidogrel metabolism, potentially attenuating P2Y12 receptor inhibition.
WHAT THE STUDY ADDS
• In patients treated with clopidogrel after successful drug-eluting stent implantation, the concomitant administration of a proton pump inhibitors was associated with high platelet reactivity.
• Discharge on a proton pump inhibitors was independently associated with a greater rate of adverse outcomes during long-term follow-up.
• The risk-benefit ratio of proton pump inhibitors should be carefully considered for patients with drug-eluting stent treated with clopidogrel. Proton Pump Inhibitor Interactions With Clopidogrel receiving PPI were older, more often female, with higher rates of hypertension, and having diabetes mellitus, peripheral arterial disease, chronic kidney disease, and a greater burden of established cardiovascular disease.
Effect of PPI on Platelet Reactivity
After clopidogrel loading, PRU values were significantly higher in patients prescribed PPI therapy at the time of PCI than in those not taking a PPI (201.9±97.4 versus 181.6±95.8, P<0.0001). A significantly greater proportion of patients on PPI therapy had HPR defined as a PRU cutoff of either >208 (49.3% versus 39.7%, P<0.0001) or ≥230 (41.1% versus 32.3%, P<0.0001; Table 2 ). By linear regression, use of PPI was an independent predictor of greater PRU (P<0.0001) and was independently associated with HPR as defined as PRU>208 (odds ratio, 1.38; 95% confidence interval [CI], 1.25-1.52, P=0.0001).
Effect of PPIs on Clinical Outcomes
PPI use had no significant impact on in-hospital mortality, MI, stent thrombosis, or clinically relevant bleeding (Table 3) . At hospital discharge, 2162 (25.2%) patients were prescribed PPI therapy. Significant differences in patient characteristics similar to those with PPI use on admission were observed stratified by PPI use at hospital discharge (Table 4) . A greater proportion of patients had HPR (PRU>208) in the group receiving PPI therapy at discharge (48.5% versus 40.8%, P<0.0001). As shown in Table 5 and Figure, after excluding in-hospital events, patients discharged on PPI therapy had higher 2-year rates of all-cause mortality, clinically-driven target vessel revascularization, and MACE, with nonsignificant differences in MI and stent thrombosis. In propensity-adjusted proportional hazards regression models, PPI use was independently associated with postdischarge 2-year rates of MACE (hazard ratio, 1.21; 95% CI, 1.04-1.40, P=0.02) and clinically-driven target vessel revascularization (hazard ratio, 1.27; 95% CI, 1.09-1.49, P=0.0027), with a strong trend present toward mortality (hazard ratio, 1.28; 95% CI, 1.00-1.63, P=0.051; Table 5 ). PPI use was not associated with increased out-ofhospital clinically relevant bleeding at 2 years (hazard ratio 1.03; 95% CI 0.84-1.26, P=0.76).
Discussion
Recent studies investigating the safety of PPI therapy in patients requiring DAPT with aspirin and clopidogrel have reported conflicting data. To our knowledge, the present analysis is the first large-scale study to correlate PPI use, the results of platelet reactivity testing, and long-term adverse clinical outcomes in a large, real-world population of patients undergoing PCI with DES. We observed that (1) PPI therapy at the time of PCI was associated with several high-risk baseline characteristics but remained independently associated with HPR on clopidogrel, consistent with known effects of certain PPIs to interfere with clopidogrel metabolism; (2) PPI use did not correlate with short-term in-hospital outcomes after successful DES, likely because of a small number of inhospital events; and (3) by propensity-adjusted multivariable analysis, PPI prescription at hospital discharge was independently associated with MACE, clinically driven target vessel revascularization, and a trend toward long-term mortality during 2-year follow-up.
Although multiple observational population-based studies have reported an increased incidence of MACE with concomitant clopidogrel and PPI use, 10, 16, 17, 22 other registries and post hoc analyses have yielded inconclusive results or found no increased risk. [11] [12] [13] [14] [15] 23 A recent meta-analysis of trials evaluating PPI safety in patients with coronary disease on DAPT also demonstrated no increased cardiovascular risk. 24 
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The only large randomized trial of PPI compared with placebo in patients with cardiovascular disease and an indication for DAPT (which used a noncommercial time-dose release formulation of clopidogrel plus omeprazole compared with clopidogrel alone) demonstrated that prophylactic PPI therapy reduced rates of bleeding (particularly gastrointestinal bleeding) with no apparent impact on cardiovascular events. 9 However, the trial was prematurely terminated for financial reasons, providing limited power from which to draw definitive conclusions.
Although the observation of higher platelet reactivity among PPI-treated patients may partially have been modulated by the coexistence of other risk factors for HPR in patients treated with PPI, a plausible biological mechanism for an interaction between PPI and clopidogrel exists. Clopidogrel is a prodrug that undergoes a 2-step metabolic transformation to its active metabolite before binding to the P2Y12 ADP receptor on the platelet surface. The conversion of clopidogrel to its active metabolite relies principally on the CYP2C19 allele of the hepatic cytochrome P-450 system. 25 Studies have demonstrated that loss-of-function genetic polymorphisms of CYP2C19 are associated with increased risks of on-clopidogrel cardiovascular events, especially stent thrombosis. 26 Selected PPIs also undergo metabolism by the CYP2C19 isoenzyme, and concomitant PPI therapy can competitively blunt the efficacy of P2Y12-mediated platelet inhibition. 27 Clinical trials of omeprazole and clopidogrel in combination demonstrated a decreased inhibitory effect on platelet P2Y12 activity. 5, 6 Based on these data, the US Food and Drug Administration has warned of a potential drug interaction between clopidogrel and omeprazole and discourage combination therapy in the absence of a compelling clinical indication. 28 The impact of attenuated clopidogrel antiplatelet effects is particularly relevant after PCI because high on-treatment platelet reactivity has consistently been linked to increased rates of MI, stent thrombosis, and cardiovascular mortality. [29] [30] [31] [32] The results presented in this large-scale study support both the existence of a clinically meaningful interaction and the postulated mechanism of the increased hazard for MACE with PPI therapy by demonstrating an associated attenuation of clopidogrel antiplatelet activity as measured by PRU.
Study Limitations
There are several limitations to this nonrandomized, observational study. First, the use of PPI therapy was documented as the class, and assessment of individual PPI-specific effects are not possible from this study. Although omeprazole (the most widely used PPI) is well established as a CYP2C19 inhibitor that can affect clopidogrel metabolism, other PPIs seem to lack this interaction. Pantoprazole, for example, is not characterized by CYP2C19 interactions and does not attenuate the pharmacodynamic effects of clopidogrel. 33, 34 Therefore, it is possible that the effect on platelet reactivity and MACE for PPIs known to inhibit clopidogrel metabolism, such as omeprazole, may be greater than the 21% observed herein. Additionally, the use of other classes of gastroprotective therapies (such as H2 blockers) was not assessed in this study. Second, the frequency of CYP2C19 CABG indicates coronary artery bypass graft surgery; CAD, coronary artery disease; LV, left ventricular; NSTEMI, non-ST-segment-elevation myocardial infarction; PCI, percutaneous coronary intervention; PPI, proton pump inhibitor; STEMI, ST-segment-elevation myocardial infarction; and UA, unstable angina. Proton Pump Inhibitor Interactions With Clopidogrel variant alleles was not studied in this registry. Therefore, genetic disequilibrium among patients treated with and without PPI cannot be excluded. Third, PPI use was not randomized, the indication(s) to treat with PPI therapy on admission or discharge were not documented, and high-risk baseline characteristics were more commonly associated with PPI use. Confounding Data are Kaplan-Meier estimates displayed as % (n events). HR adjusted for age, sex, diabetes mellitus, hypertension, hyperlipidemia, tobacco use, prior MI, renal insufficiency, creatinine clearance, STEMI or NSTEMI, one treated vessel, hemoglobin, WBC, platelet count, VerifyNow P2Y12>208, and propensity score as a quintile variable. CI indicates confidence interval; HR, hazard ratio; MACE indicates major adverse cardiac events (death, myocardial infarction, stent thrombosis, or clinically driven target vessel revascularization); MI, myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; PPI, proton pump inhibitor; STEMI, ST-segment-elevation myocardial infarction; TVR, target vessel revascularization; and WBC, white blood count.
*Because of a limited number of events, only PPI use at discharge and propensity score quintiles were included in the stent thrombosis model. In-hospital events were censored from this landmark analysis, and time 0 represents the date of discharge. Proton Pump Inhibitor Interactions With Clopidogrel likely underlies the borderline relationship observed between discharge PPI use and out-of-hospital bleeding in unadjusted analysis, and some degree of residual confounding from unmeasured variables after propensity-adjusted analysis cannot be excluded. PPI use was not, however, associated with increased bleeding in the adjusted model, and therefore, the adverse effects of bleeding on mortality cannot account for the reduced survival associated with PPI. Nonetheless, post hoc analysis from even a large-scale prospective registry cannot establish causality between PPI therapy and cardiovascular events because the lack of randomization can lead to potential biases. Fourth, although the vast majority of patients were followed for 2 years, the dose, duration, interruption, and discontinuation of PPI or antiplatelet therapy after hospital discharge were not evaluated. Drug exposure is a critical time-dependent covariate that may modulate clopidogrel-mediated platelet inhibition and may impact the calculated hazard; however, crossover of therapy in both the PPI and non-PPI groups would be expected to bias the results toward the null and diminish the observed effect size. Differences in end point ascertainment at 2-year follow-up in patients with and without discharge PPI use were also observed, and attrition bias may have contributed to the study findings. Fifth, VerifyNow platelet reactivity testing was performed only once during the index hospitalization. As platelet reactivity on clopidogrel can vary significantly over time, we cannot exclude misclassification of the response to clopidogrel that could confound the observed relationship between PPI use and HPR and may affect longterm clinical events. 35 Finally, the mechanism of significantly greater ischemia-driven target vessel revascularization observed among patients treated with PPI remains uncertain. The lack of a significant relationship between stent thrombosis and PPI use may be because of the relatively low frequency of stent thrombosis in this study, because of predominant use of second generation DES, which are known to reduce stent thrombosis, 36 and because of exclusion of patients with peri-procedural complications. Therefore, our study may have underestimated the clinical impact of PPI-induced HPR on MACE, MI, and stent thrombosis events post-PCI.
Conclusions
In conclusion, in patients treated with aspirin and clopidogrel after successful DES implantation in the large-scale, prospective ADAPT-DES study, the concomitant administration of a PPI was associated with HPR and an increased rate of MACE occurring during 2-year follow-up. Additional studies are warranted to determine the risk-benefit ratio of PPI use in patients with DES in whom clopidogrel is used to inhibit the P2Y12 platelet receptor.
